fosamprenavir

Known as: (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester, fos-amprenavir, fosamprenavir [Chemical/Ingredient] 
A prodrug form of amprenavir. In the body fosamprenavir is metabolized to amprenavir, a synthetic derivative of hydroxyethylamine sulfonamide that… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
BACKGROUND The role of exposure to specific antiretroviral drugs on risk of myocardial infarction in human immunodeficiency virus… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2009
Review
2009
In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of… (More)
  • figure 2
  • figure 1
  • figure 3
  • table 1
  • figure 6
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Table o f contents 1.0 Introduction 2.0 Methodology 2.1 Basing recommendations o n evidence 2.2 Implications for research 2.3 Use… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2008
2008
BACKGROUND Rosuvastatin (RSV) is a potent statin with a lower potential for drug interactions. However, recent data have revealed… (More)
Is this relevant?
2008
2008
BACKGROUND Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus… (More)
  • table 1
  • figure 4
  • table 2
Is this relevant?
2007
2007
In this study, named the Zephir study (Telzir-pharmacokinetics), 121 antiretroviral-experienced human immunodeficiency virus (HIV… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir… (More)
Is this relevant?
Review
2006
Review
2006
Fosamprenavir is one of the most recently approved HIV-1 protease inhibitors (PIs) and offers reductions in pill number and pill… (More)
Is this relevant?
2004
2004
BACKGROUND In vitro synergy and complementary resistance profiles provide a strong rationale for combining fosamprenavir with… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To compare the magnitude and durability of the antiviral response to fosamprenavir (FPV) plus ritonavir (RTV) once… (More)
Is this relevant?